Table 4.

Univariable analysis of LFS in the cohort of patients analyzed

Number of patientsEventsProbability95% CIPHR*(95% CI)P
All patients 343 124 62% 56-67     
Sex         
 Male 210 66 66% 58-73 .015    
 Female 133 58 55% 47-64  1.54 1.07-2.20 .016 
Age at HSCT, y         
 <9.5 172 57 65% 58-73 .218    
 ≥9.5 171 67 58% 50-66  1.25 0.88-1.78 .218 
 <6 94 33 64% 54-74 .165    
 6-9.5 78 24 66% 54-78  0.82 0.48-1.39 .460 
 9.5-13 80 26 65% 53-77  0.91 0.54-1.51 .705 
 ≥13 91 41 52% 41-63  1.37 0.87-2.17 .178 
 <13 252 83 65% 59-72 .032    
 ≥13 91 41 52% 41-63  1.50 1.03-2.18 .033 
Diagnosis         
 ALL 237 93 59% 52-66 .064    
 AML 106 31 67% 57-78  0.68 0.45-1.03 .066 
ALL phenotype         
 B-cell precursor 191 74 59% 50-66 .713    
 T-cell precursor 47 19 59% 45-73  0.91 0.55-1.50 .713 
Disease phase at HSCT         
 Only ALL patients         
  CR1† 93 31 66.7% 56-76 .0005    
  CR2 S1-S2† 85 26 69.4% 58-79  0.89 0.53-1.49 .651 
  CR2 S3-S4‡ 49 29 40.8% 24-53  2.11 1.27-3.51 .004 
  Other CR‡ 11 7 36.4% 8-64  2.74 1.21-6.24 .016 
 Only AML patients         
  CR1† 82 23 72% 56-80 .084    
  CR2† 22 7 68.2% 48-88  1.25 0.54-2.91 .607 
Prognosis†,‡         
 Good prognosis† 282 87 67% 62-73 .0001    
 Poor prognosis‡ 61 37 37% 23-50  2.54 1.73-3.74 .0001 
MRD, all patients         
 <1 × 10−3 143 52 63% 54-71     
 ≥1 × 10−3 20 13 20% 0-49 .003 2.48 1.35-4.56 .004 
 Neg 119 39 66% 58-75     
 Pos <1 × 10−3 24 13 42% 20-63  1.68 0.90-3.16 .105 
 Pos ≥1 × 10−3 20 16 20% 0-49 .003 2.76 1.47-5.19 .002 
MRD, only ALL patients         
 <1 × 10−3 121 46 61% 52-70     
 ≥1 × 10−3 11 7 36% 8-65 .046 2.20 0.99-4.88 .052 
 Neg 98 33 66% 57-75     
 Pos <1 × 10−3 23 13 39% 17-61  1.70 0.89-3.23 .110 
 Pos ≥1 × 10−3 11 7 36% 8-65 .040 2.49 1.10-5.64 .028 
MRD, only AML patients         
 <1 × 10−3 22 6 72% 52-91     
 ≥1 × 10−3 9 6 0% — .010 4.14 1.28-13.38 .017 
 Neg 21 6 70% 50-90     
 Pos ≥1 × 10−3 9 9 0% — .033 3.92 1.22-12.65 .022 
Donor         
 MUD 245 90 63.3% 65-68 .650    
 Haploidentical 98 34 65.3% 51-73  1095 0.74-1.63 .650 
HLA compatibility         
 MUD 127 40 67% 59-76 .150    
 MMUD 118 50 55% 45-65  1.48 0.98-2.25 .063 
 Haploidentical 98 34 62% 51-73  1.11 0.71-1.76 .642 
Stem cell source         
 BM 187 68 64% 55-69 .731    
 PBSC 156 56 64% 53-70  1.064 0.75-1.52 .731 
Conditioning regimen         
 TBI-based 204 73 64% 54-69 .673    
 Busulfan-based 115 40 65% 53-72  0.95 0.64-1.39 .783 
 Treosulfan-based 21 10 52% 28-72  1.45 0.75-2.81 .270 
Conditioning regimen, ALL patients         
 TBI-based 189 69 61% 53-69 .004    
 Busulfan-based 34 14 59% 42-75  1.20 0.68-2.13 .532 
 Treosulfan-based 12 10 17% 0-38  3.11 1.60-6.06 .001 
Conditioning regimen, AML patients         
 TBI-based 15 4 73% 51-96 .155    
 Busulfan-based 81 26 65% 53-76  1.14 0.40-3.27 .805 
 Treosulfan-based 9 0 100% —  0.00 — <.001 
Number of patientsEventsProbability95% CIPHR*(95% CI)P
All patients 343 124 62% 56-67     
Sex         
 Male 210 66 66% 58-73 .015    
 Female 133 58 55% 47-64  1.54 1.07-2.20 .016 
Age at HSCT, y         
 <9.5 172 57 65% 58-73 .218    
 ≥9.5 171 67 58% 50-66  1.25 0.88-1.78 .218 
 <6 94 33 64% 54-74 .165    
 6-9.5 78 24 66% 54-78  0.82 0.48-1.39 .460 
 9.5-13 80 26 65% 53-77  0.91 0.54-1.51 .705 
 ≥13 91 41 52% 41-63  1.37 0.87-2.17 .178 
 <13 252 83 65% 59-72 .032    
 ≥13 91 41 52% 41-63  1.50 1.03-2.18 .033 
Diagnosis         
 ALL 237 93 59% 52-66 .064    
 AML 106 31 67% 57-78  0.68 0.45-1.03 .066 
ALL phenotype         
 B-cell precursor 191 74 59% 50-66 .713    
 T-cell precursor 47 19 59% 45-73  0.91 0.55-1.50 .713 
Disease phase at HSCT         
 Only ALL patients         
  CR1† 93 31 66.7% 56-76 .0005    
  CR2 S1-S2† 85 26 69.4% 58-79  0.89 0.53-1.49 .651 
  CR2 S3-S4‡ 49 29 40.8% 24-53  2.11 1.27-3.51 .004 
  Other CR‡ 11 7 36.4% 8-64  2.74 1.21-6.24 .016 
 Only AML patients         
  CR1† 82 23 72% 56-80 .084    
  CR2† 22 7 68.2% 48-88  1.25 0.54-2.91 .607 
Prognosis†,‡         
 Good prognosis† 282 87 67% 62-73 .0001    
 Poor prognosis‡ 61 37 37% 23-50  2.54 1.73-3.74 .0001 
MRD, all patients         
 <1 × 10−3 143 52 63% 54-71     
 ≥1 × 10−3 20 13 20% 0-49 .003 2.48 1.35-4.56 .004 
 Neg 119 39 66% 58-75     
 Pos <1 × 10−3 24 13 42% 20-63  1.68 0.90-3.16 .105 
 Pos ≥1 × 10−3 20 16 20% 0-49 .003 2.76 1.47-5.19 .002 
MRD, only ALL patients         
 <1 × 10−3 121 46 61% 52-70     
 ≥1 × 10−3 11 7 36% 8-65 .046 2.20 0.99-4.88 .052 
 Neg 98 33 66% 57-75     
 Pos <1 × 10−3 23 13 39% 17-61  1.70 0.89-3.23 .110 
 Pos ≥1 × 10−3 11 7 36% 8-65 .040 2.49 1.10-5.64 .028 
MRD, only AML patients         
 <1 × 10−3 22 6 72% 52-91     
 ≥1 × 10−3 9 6 0% — .010 4.14 1.28-13.38 .017 
 Neg 21 6 70% 50-90     
 Pos ≥1 × 10−3 9 9 0% — .033 3.92 1.22-12.65 .022 
Donor         
 MUD 245 90 63.3% 65-68 .650    
 Haploidentical 98 34 65.3% 51-73  1095 0.74-1.63 .650 
HLA compatibility         
 MUD 127 40 67% 59-76 .150    
 MMUD 118 50 55% 45-65  1.48 0.98-2.25 .063 
 Haploidentical 98 34 62% 51-73  1.11 0.71-1.76 .642 
Stem cell source         
 BM 187 68 64% 55-69 .731    
 PBSC 156 56 64% 53-70  1.064 0.75-1.52 .731 
Conditioning regimen         
 TBI-based 204 73 64% 54-69 .673    
 Busulfan-based 115 40 65% 53-72  0.95 0.64-1.39 .783 
 Treosulfan-based 21 10 52% 28-72  1.45 0.75-2.81 .270 
Conditioning regimen, ALL patients         
 TBI-based 189 69 61% 53-69 .004    
 Busulfan-based 34 14 59% 42-75  1.20 0.68-2.13 .532 
 Treosulfan-based 12 10 17% 0-38  3.11 1.60-6.06 .001 
Conditioning regimen, AML patients         
 TBI-based 15 4 73% 51-96 .155    
 Busulfan-based 81 26 65% 53-76  1.14 0.40-3.27 .805 
 Treosulfan-based 9 0 100% —  0.00 — <.001 

Subgroups including fewer than 5 patients were not shown in the table.

*

The Cox regression model was used to estimate the HR, and the first subgroup of patients of each independent variable was used as reference value.

†

The good prognosis group included patients affected by ALL in first CR, ALL in second CR after a relapse belonging to the S1-S2 risk groups and patients with AML in first CR.

‡

The poor-prognosis group included patients affected by ALL in second CR after a relapse belonging to the S3-S4 risk groups, ALL in third or subsequent CR, and patients with AML in second CR.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal